The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Granules India Ltd. (Granules) is a vertically integrated pharmaceutical company that specialises in the development, manufacturing, and distribution of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The company's core products include Ibuprofen, Metformin, Paracetamol, Methocarbamol, and Guaifenesin. Granules also operates a consumer health division, Granules Consumer Health (GCH), which focuses on large-volume pharmaceutical products. The company's products are used by a diverse range of customers, including leading generic and branded pharmaceutical companies, in both regulated and semi-regulated markets. Its target markets include the US, Canada and India, among others. Granules is headquartered in Hyderabad, Telangana, India.Granules India Ltd Key Recent Developments
- Nov 13, 2025: Q2FY26 Revenue from operations at INR 12.97 billion up 34% YoY, EBITDA at INR 2.78 billion up 37% YoY, PBT at INR 1.75 billion up 37% YoY, PAT at INR 1.30 billion up 34% YoY
- Oct 29, 2025: Granules India’s Unit I Facility Secures US FDA EIR With 'Voluntary Action Indicated' (VAI)
- Aug 12, 2025: Granules India Announces Results for Quarter Ended June 30, 2025
- Jul 22, 2025: 48 Projects Have Been Approved Under the Production Linked Incentive Scheme for Promotion of Domestic Manufacturing of Critical Ksms / Dis and Active Pharmaceutical Ingredients (APIs) in India
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bal Pharma Ltd
- Hikal Ltd
- Ind-Swift Laboratories Ltd
- Mankind Pharma Ltd
- Divi's Laboratories Ltd
- Concord Biotech Ltd

